Skip to main content
Signal8
Launch Terminal

Quince Therapeutics, Inc. (IRLA)

IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

IRulya Therapeutics Inc. logo

IRulya Therapeutics Inc.

NASDAQ:IRLAHealthcare
-5.14%$31.38
AH Close$31.38+0.00%vs close
Mkt Cap$31.92M
Float1.93M
O/S1.02M
Inst Own32.5%
Dilution
IRulya Therapeutics Inc. logoNASDAQ:IRLA$31.38-5.14%
FormDescription
144
Notice of Proposed Sale of Securities
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
8-K
7.01,9.01
3
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
2
8-K
5.02,5.03,7.01,8.01,9.01
4
S-8
SEC Filing
2
8-K
5.02,5.03,5.07,9.01
5
DEFA14A
Additional Proxy Materials
3
8-K
5.02
2
8-K
2.01,5.02,9.01
5
8-K
3.01
4
8-K
5.02
3
DEF 14A
Definitive Proxy Statement
8
EFFECT
Notice of Effectiveness
2
8-K
8.01,9.01
5
13G
Beneficial Ownership Report
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
7
13G
Beneficial Ownership Report

1-25 of 461

…